Normunity
Business Services · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 College St, New Haven, Connecticut, ...Phone Number
(203) 993-6580Website
www.normunity.comRevenue
$5.1 MillionIndustry
About Normunity
Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The companys lead program, NRM823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025. Normunity is located in Boston, MA, and New Haven, CT. For more information, please visit www.normunity.com and follow us on LinkedIn.Explore more
Normunity Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Normunity
Compare insights from companies similar to Normunity, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Normunity Tech Stack
A closer look at the technologies used by Normunity
Top Business Services Companies
Frequently Asked Questions Regarding Normunity
Sign Up For FreeTo access detailed company insights
Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, inclu... Read More
